Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
about
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinomaProstacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapySinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expressionCyclooxygenase-2 and the inflammogenesis of breast cancer.Seeing it through: translational validation of new medical imaging modalities.Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors.Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinasesCyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenomaRestoration of leukotriene B(4)-12-hydroxydehydrogenase/15- oxo-prostaglandin 13-reductase (LTBDH/PGR) expression inhibits lung cancer growth in vitro and in vivo.Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agentsOverexpression of lecithin:retinol acyltransferase in the epithelial basal layer makes mice more sensitive to oral cavity carcinogenesis induced by a carcinogen.An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells.Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinomaRegulation of COX-2 expression by miR-146a in lung cancer cellsRole of vitamin and mineral supplementation and aspirin use in cancer survivorsStromal, rather than epithelial cyclooxygenase-2 (COX-2) expression is associated with overall survival of breast cancer patients.Animal models and therapeutic molecular targets of cancer: utility and limitations.Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme.The role of chalcones in suppression of NF-κB-mediated inflammation and cancer.Role of LKB1-CRTC1 on glycosylated COX-2 and response to COX-2 inhibition in lung cancer.Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancerChemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma.Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerA novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cellsSimultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.Inflammation and cancer: chemical approaches to mechanisms, imaging, and treatment.Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.Chemoprevention of hormone receptor-negative breast cancer: new approaches neededSynergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.American Society of Clinical Oncology 41st annual meeting.Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine modelEpidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer.Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy.Targeting tumor metastases: Drug delivery mechanisms and technologies.What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?
P2860
Q21563424-9978078B-03A3-43C1-AB45-19AE262F1DC7Q24303556-15154549-B308-4459-80AC-3012D867FA32Q28242840-C7B1B05C-FA5A-42CC-93B7-0FE062FC4997Q28539407-3A849788-FF69-4D85-8C82-5213431A868FQ30367680-8A18A838-FD71-42A5-9CC2-FEDC2C7FB34DQ30467703-8E4A2A2F-7ECF-419B-8951-07A38FBC3A52Q30481023-C47A40C4-CFDD-4513-A385-9FCF84CD9DA1Q33302631-7D4C3D86-2E67-44BB-A2BD-65C59E80366AQ33317095-7075F9E1-1F06-4ED9-8C93-A67D387AB1FDQ33759512-128FF6E1-8C79-438B-9B01-9072FF4432DFQ33829659-55E6AA8B-8B74-4739-B824-DD22CD49D3BCQ33901872-B267B5FF-1401-4931-BAB1-2C9BA0286AA8Q33960748-CB0C92CA-C319-429C-9B52-5EF91C3912EFQ33980773-1DF43252-55B3-4E31-810A-0447A1660A89Q34021476-F03C340E-D952-4875-9B40-FC895A7968CBQ34067248-FF762FD3-E115-4E55-85C7-8D111435D9E6Q34130572-ADC74860-DB83-462C-8DAC-0775CE696B23Q34316720-ED7D6BD6-1223-46D8-BCBA-73137EAD66F3Q34386828-C50AE0EF-73B1-4348-A736-9C28D9FF206EQ34637939-D635D00C-1755-47A0-BA9B-7E44E0E2CE2AQ34682265-93FC2AEA-3D31-4929-9EEE-E3615DD66630Q34736608-77E81069-CD10-4902-B3F0-29BE2DDC0F0FQ35082216-201C3EFE-6DE7-406C-8970-4017D24D712FQ35154257-C199FA3B-1219-45A9-A1FB-370BCC78817AQ35575874-70E598BA-50CB-493A-BC2F-7B5B900CB828Q35631181-FA613AD4-3221-4C20-ACAA-AE8289152CFFQ35633657-AC820818-3B45-4EFD-864F-5CA8D8F678D6Q35673201-95EC0DC2-F1CA-436C-B7F9-D76DD0B7D18DQ35968264-5E393E54-DC12-4C02-A630-9D4727B7DA62Q36033937-FBCA4F41-813A-428B-AA38-0DD14C665287Q36095128-6C9A4757-80B0-4761-B803-28F4DA27509FQ36153371-686DAEA6-97C4-473A-AF15-CDDCA7CFD44DQ36185717-DE64A3F3-460E-403C-818C-6AACFA7399C1Q36210888-14022B4A-E25A-4C17-B20B-2833D14BAD60Q36215333-7C8F6A03-AB8E-4894-89C8-2FC2FA78253EQ36356814-F5E70AD4-49FB-48EE-AB5A-2ADC30374157Q36412351-4FF4F83E-7970-4CEA-AF57-BEAE5FF0C7A4Q36482809-F6D29C11-EBF9-48F1-9CC3-039EE5230D19Q36557855-0EE7DBF5-D043-4E2B-8EB4-D4C5C6780954Q36572139-706E4D3E-7F6B-4371-ABBD-68AAC7E9E531
P2860
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@ast
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@en
type
label
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@ast
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@en
prefLabel
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@ast
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@en
P2093
P356
P1476
Cyclooxygenase-2 and epidermal ...... c targets for chemoprevention.
@en
P2093
Andrew J Dannenberg
Jason R Mann
Kotha Subbaramaiah
Raymond N DuBois
Scott M Lippman
P304
P356
10.1200/JCO.2005.09.112
P407
P577
2005-01-01T00:00:00Z